59 related articles for article (PubMed ID: 31530111)
1. Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies.
Wang C; Li H; Chen WC; Lu N; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2019; 29(5):731-748. PubMed ID: 31530111
[TBL] [Abstract][Full Text] [Related]
2. Covariate handling approaches in combination with dynamic borrowing for hybrid control studies.
Fu C; Pang H; Zhou S; Zhu J
Pharm Stat; 2023; 22(4):619-632. PubMed ID: 36882191
[TBL] [Abstract][Full Text] [Related]
3. Propensity score stratified MAP prior and posterior inference for incorporating information across multiple potentially heterogeneous data sources.
Zhu AY; Roy D; Zhu Z; Sailer MO
J Biopharm Stat; 2024 Mar; 34(2):190-204. PubMed ID: 36882957
[TBL] [Abstract][Full Text] [Related]
4. Propensity score-incorporated adaptive design approaches when incorporating real-world data.
Lu N; Chen WC; Li H; Song C; Tiwari R; Wang C; Xu Y; Yue LQ
Pharm Stat; 2024; 23(2):204-218. PubMed ID: 38014753
[TBL] [Abstract][Full Text] [Related]
5. Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL).
Majumdar A; Rothwell R; Reaman G; Ahlberg C; Roy P
J Biopharm Stat; 2023 Nov; 33(6):737-751. PubMed ID: 36600441
[TBL] [Abstract][Full Text] [Related]
6. Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation.
Eichler HG; Koenig F; Arlett P; Enzmann H; Humphreys A; Pétavy F; Schwarzer-Daum B; Sepodes B; Vamvakas S; Rasi G
Clin Pharmacol Ther; 2020 Apr; 107(4):773-779. PubMed ID: 31574163
[TBL] [Abstract][Full Text] [Related]
7. Propensity score weighted multi-source exchangeability models for incorporating external control data in randomized clinical trials.
Wei W; Zhang Y; Roychoudhury S;
Stat Med; 2024 Jun; ():. PubMed ID: 38924575
[TBL] [Abstract][Full Text] [Related]
8. Adaptively leverage multiple real-world data sources for treatment effect estimation based on similarity.
Long M; Song J; Rong Z; Mi L; Song Y; Hou Y
J Biopharm Stat; 2024 Apr; ():1-11. PubMed ID: 38557411
[TBL] [Abstract][Full Text] [Related]
9. Advancing regulatory science through real-world data and real-world evidence.
Cure P; Fessel JP; Hartshorn CM; Steele SJ
J Clin Transl Sci; 2024; 8(1):e87. PubMed ID: 38784107
[No Abstract] [Full Text] [Related]
10. Complications in Using Real-World Data to Study the Health of People Who Use Drugs.
Figgatt MC; Schranz AJ; Hincapie-Castillo JM; Golightly YM; Marshall SW; Dasgupta N
Epidemiology; 2023 Mar; 34(2):259-264. PubMed ID: 36722808
[No Abstract] [Full Text] [Related]
11. Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data.
Chen WC; Wang C; Li H; Lu N; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2020 May; 30(3):508-520. PubMed ID: 32370640
[TBL] [Abstract][Full Text] [Related]
12. Propensity score-integrated composite likelihood approach for incorporating real-world evidence in single-arm clinical studies.
Wang C; Lu N; Chen WC; Li H; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2020 May; 30(3):495-507. PubMed ID: 31707908
[TBL] [Abstract][Full Text] [Related]
13. Leverage multiple real-world data sources in single-arm medical device clinical studies.
Lu N; Wang C; Chen WC; Li H; Song C; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2022 Jan; 32(1):107-123. PubMed ID: 33844621
[TBL] [Abstract][Full Text] [Related]
14. Leveraging real-world evidence for determining performance goals for medical device studies.
Wang C; Rosner GL; Bao T; Lu N; Chen WC; Li H; Tiwari R; Xu Y; Yue LQ
Stat Med; 2021 Dec; 40(29):6577-6589. PubMed ID: 34561895
[TBL] [Abstract][Full Text] [Related]
15. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
16. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
17. Using Bayesian statistics in confirmatory clinical trials in the regulatory setting: a tutorial review.
Lee SY
BMC Med Res Methodol; 2024 May; 24(1):110. PubMed ID: 38714936
[TBL] [Abstract][Full Text] [Related]
18. Case weighted power priors for hybrid control analyses with time-to-event data.
Kwiatkowski E; Zhu J; Li X; Pang H; Lieberman G; Psioda MA
Biometrics; 2024 Mar; 80(2):. PubMed ID: 38536747
[TBL] [Abstract][Full Text] [Related]
19. Bayesian approach for design and analysis of medical device trials in the era of modern clinical studies.
Cao H; Yao C; Yuan Y
Med Rev (2021); 2023 Oct; 3(5):408-424. PubMed ID: 38283256
[TBL] [Abstract][Full Text] [Related]
20. Sequential regression and simulation: a method for estimating causal effects from heterogeneous clinical trials without a common control group.
Rudrapatna VA; Ravindranath VG; Arneson DV; Mosenia A; Butte AJ; Wang S
BMC Med Res Methodol; 2023 Oct; 23(1):218. PubMed ID: 37789257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
